SHR-A1811

Clinical trials for SHR-A1811 explained in plain language.

Never miss a new study

Get alerted when new SHR-A1811 trials appear

Sign up with your email to follow new studies for SHR-A1811, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New targeted drug combo aims to shrink tumors before surgery, spare patients harsh chemo

Disease control Not yet recruiting

This study is testing a new combination of two targeted drugs, SHR-A1811 and pertuzumab, given before surgery for a specific type of breast cancer that is both hormone receptor-positive (HR+) and HER2-positive. The goal is to see if this approach can effectively shrink or elimina…

Matched conditions: SHR-A1811

Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control

Last updated Apr 02, 2026 09:11 UTC

SHR-A1811

Get alerted when new SHR-A1811 trials appear

New targeted drug combo aims to shrink tumors before surgery, spare patients harsh chemo